Related Experiment Video
Updated: Jul 12, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Abiraterone-Induced Endocrinopathies
Scarlett Decamps1,2, Rita Lis1,2, Preethika Ekanayake1,2
1Division of Endocrinology, Diabetes and Metabolism, University of California, San Diego, 9350 Campus Point Drive, La Jolla, CA 92037, USA.
Abstract:
Abiraterone, a CYP17A1 inhibitor, is used along with prednisone in patients with castration-resistant and castration-sensitive prostate cancer, yielding improved overall and disease-free survival. However, little is documented in the endocrinology literature about the incidences of the endocrine side effects of abiraterone. In this case series, we discuss the diagnosis and management of 3 prostate cancer patients who experienced mineralocorticoid excess and secondary adrenal insufficiency related to abiraterone and prednisone use.
Related Concept Videos
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Adrenal Gland Disorders
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Acute Kidney Injury II: Pathophysiology
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Infertility in Males
Antihypertensive Drugs: Direct Renin Inhibitors

